Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
It is unknown if this medicine passes into your breast milk
A pilot human safety study with n=2 is far too small to support broad safety claims, and regulatory sources flag concerns about unapproved use, dose uncertainty, impurities, and lack of established therapeutic dosing [10][1516]
The program is designed for sustainable management, not rapid loss
New England Journal of Medicine (2025) This phase 3b open-label trial provided the first direct head-to-head comparison of tirzepatide and semaglutide for obesity, randomizing 751 adults without diabetes to maximum tolerated doses of tirzepatide (10 or 15mg weekly) or semaglutide (1.7 or 2.4mg weekly) for 72 weeks
US$ 25.20
US$ 25.25
US$ 28.69
